NCT03492125 2025-04-10
A Study Of The Selective PKC-β Inhibitor MS- 553
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT04419389 2025-03-17
R/R
Aprea Therapeutics
Phase 1/2 Terminated
NCT04016805 2023-07-24
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03205046 2021-01-06
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Acerta Pharma BV
Phase 1/2 Terminated